Two Pharmaceutical Innovations from Nanolattix Selected for the 2026 AACR Annual Meeting
Release time:
2026-01-30
Recently, the research and development achievements of Nanolattix have garnered significant attention from the international academic community. Two research abstracts submitted by the company to the 2026 American Association for Cancer Research (AACR) Annual Meeting have been accepted and will be presented globally at the meeting, held from April 17 to 22 in San Diego, USA.
The AACR Annual Meeting is a premier global event in the field of cancer research. While Nanolattix’s T320 project has already entered Phase I clinical trials, significant progress has also been made in the development of its novel drug candidates, B836 and RT01. The two selected studies focus on two cutting-edge directions: bispecific antibody-drug conjugates (ADCs) and radionuclide drug conjugates (RDCs), fully demonstrating the company’s sustained and comprehensive innovation capabilities in tumor-targeted therapy and precision medicine.
One of the abstracts is titled “B836: A Novel Bispecific Antibody-Drug Conjugate (ADC) as a Clinical Candidate to Overcome Trastuzumab Deruxtecan Resistance.” This study addresses the current challenge of drug resistance in HER2-targeted therapy, proposing a promising next-generation bispecific ADC solution.
The other abstract, “RT01: A Novel Anti-TF Radionuclide Drug Conjugate (RDC) for Theranostic Precision Oncology,” focuses on an integrated diagnostic and therapeutic strategy that combines precise tumor diagnosis and treatment. It enables simultaneous tumor visualization and therapy through a TF-targeted radiopharmaceutical.
The simultaneous recognition of these two research achievements by AACR signifies that Nanolattix has entered the international forefront in innovative oncology drug development. It also lays a solid scientific foundation for the company’s further advancement in the global cancer treatment landscape. Nanolattix will continue to advance related preclinical and clinical studies, accelerating the translation of drug candidates into clinical applications to provide more effective treatment options for patients worldwide.
Tag:
recommend News
Share
